HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.3650
+0.0041 (1.14%)
Mar 31, 2026, 10:22 AM EDT - Market open
HCW Biologics Revenue
HCW Biologics had revenue of $15.61K in the quarter ending September 30, 2025, a decrease of -96.34%. This brings the company's revenue in the last twelve months to $422.03K, down -87.93% year-over-year. In the year 2024, HCW Biologics had annual revenue of $2.57M, down -9.68%.
Revenue (ttm)
$422.03K
Revenue Growth
-87.93%
P/S Ratio
4.92
Revenue / Employee
$11,723
Employees
36
Market Cap
2.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
| Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
| Dec 31, 2022 | 6.72M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 4.10M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.49M |
| 60 Degrees Pharmaceuticals | 1.41M |
| SciSparc | 1.31M |
| Scinai Immunotherapeutics | 1.15M |
| PMGC Holdings | 590.08K |
| Iterum Therapeutics | 390.00K |
HCWB News
- 14 days ago - HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic - GlobeNewsWire
- 15 days ago - HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - GlobeNewsWire
- 4 weeks ago - HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - GlobeNewsWire
- 5 weeks ago - HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 6 weeks ago - HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - GlobeNewsWire
- 4 months ago - HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - GlobeNewsWire
- 4 months ago - HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 5 months ago - HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire